A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma
Clinical trial NCT01226277 · COMPLETED
Trial details
- NCT number
- NCT01226277
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-10-01
- Primary completion
- 2012-09-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.